Lipidomics in Lipoprotein Biology

Lipidomics: Technologies and Applications

Volumn , Issue , 2012, Pages 197-217

  Lhomme, Marie C ^a,b,c   Camont, Laurent ^a,b,c   Chapman, M John ^a,b,c   Kontush, Anatol ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Dyslipidemia; HDL; LDL; Lipids; Lipoproteinomics; Mass spectrometry; VLDL

Indexed keywords

EID: 84885512188     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527655946.ch10     Document Type: Chapter

References (81)

1. Jung, H.R., Sylvanne, T., Koistinen, K.M., Tarasov, K., Kauhanen, D., and Ekroos, K. (2011) High throughput quantitative molecular lipidomics. Biochim. Biophys. Acta, 1811, 925-934.
2. Wiesner, P., Leidl, K., Boettcher, A., Schmitz, G., and Liebisch, G. (2009) Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res., 50, 574-585.
3. Stahlman, M., Pham, H.T., Adiels, M., Mitchell, T.W., Blanksby, S.J., Fagerberg, B., Ekroos, K., and Boren, J. (2012) Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes. Diabetologia, 55 (4), 1156-1166.
4. Kontush, A. and Chapman, M.J. (2010) Lipidomics as a tool for the study of lipoprotein metabolism. Curr. Atheroscler Rep., 12, 194-201.
5. Ivanova, P.T., Milne, S.B., Byrne, M.O., Xiang, Y., and Brown, H.A. (2007) Glycerophospholipid identification and quantitation by electrospray ionization mass spectrometry. Methods Enzymol., 432, 21-57.
6. Harkewicz, R. and Dennis, E.A. (2011) Applications of mass spectrometry to lipids and membranes. Annu. Rev. Biochem., 80, 301-325.
7. Myers, D.S., Ivanova, P.T., Milne, S.B., and Brown, H.A. (2011) Quantitative analysis of glycerophospholipids by LCMS: acquisition, data handling, and interpretation. Biochim. Biophys. Acta, 1811 (11): 748-757.
8. Hutchins, P.M., Barkley, R.M., and Murphy, R.C. (2008) Separation of cellular nonpolar neutral lipids by normal-phase chromatography and analysis by electrospray ionization mass spectrometry. J. Lipid Res., 49, 804-813.
9. Quehenberger, O., Armando, A.M., Brown, A.H., Milne, S.B., Myers, D.S., Merrill, A.H., Bandyopadhyay, S., Jones, K.N., Kelly, S., Shaner, R.L., Sullards, C. M.,Wang, E., Murphy, R.C., Barkley, R. M., Leiker, T.J., Raetz, C.R.H., Guan, Z., Laird, G.M., Six, D.A., Russell, D.W., McDonald, J.G., Subramaniam, S., Fahy, E., and Dennis, E.A. (2010) Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res., 51, 3299-3305.
10. Skipski, V.P., Barclay, M., Barclay, R.K., Fetzer, V.A., Good, J.J., and Archibald, F. M. (1967) Lipid composition of human serum lipoproteins. Biochem. J., 104, 340-352.
11. Kontush, A., Therond, P., Zerrad, A., Couturier, M., Negre-Salvayre, A., de Souza, J.A., Chantepie, S., and Chapman, M.J. (2007) Preferential sphingosine-1- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol., 27, 1843-1849.
12. Pietilainen, K.H., Sysi-Aho, M., Rissanen, A., Seppanen-Laakso, T., Yki-Jarvinen, H., Kaprio, J., and Oresic, M. (2007) Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects: a monozygotic twin study. PLoS One, 2, e218.
13. Schwab, U., Seppanen-Laakso, T., Yetukuri, L., Agren, J., Kolehmainen, M., Laaksonen, D.E., Ruskeepaa, A.L., Gylling, H., Uusitupa, M., and Oresic, M. (2008) Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism: the GENOBIN study. PLoS One, 3, e2630.
14. Lankinen, M., Schwab, U., Gopalacharyulu, P.V., Seppanen-Laakso, T., Yetukuri, L., Sysi-Aho, M., Kallio, P., Suortti, T., Laaksonen, D.E., Gylling, H., Poutanen, K., Kolehmainen, M., and Oresic, M. (2009) Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis, 20 (4): 249-257.
15. de Mello, V.D., Lankinen, M., Schwab, U., Kolehmainen, M., Lehto, S., Seppanen- Laakso, T., Oresic, M., Pulkkinen, L., Uusitupa, M., and Erkkila, A.T. (2009) Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia, 52, 2612-2615.
16. Kotronen, A., Velagapudi, V.R., Yetukuri, L., Westerbacka, J., Bergholm, R., Ekroos, K., Makkonen, J., Taskinen, M.R., Oresic, M., and Yki-Jarvinen, H. (2009) Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia, 52, 684-690.
17. Aalto-Setala, K., Laitinen, K., Erkkila, L., Leinonen, M., Jauhiainen, M., Ehnholm, C., Tamminen, M., Puolakkainen, M., Penttila, I., and Saikku, P. (2001) Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 21, 578-584.
18. Puri, P., Wiest, M.M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H.K., Contos, M.J., Sterling, R.K., Fuchs, M., Zhou, H., Watkins, S.M., and Sanyal, A.J. (2009) The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology, 50, 1827-1838.
19. Lankinen, M., Schwab, U., Erkkila, A., Seppanen-Laakso, T., Hannila, M.L., Mussalo, H., Lehto, S., Uusitupa, M., Gylling, H., and Oresic, M. (2009) Fatty fish intake decreases lipids related to inflammation and insulin signaling: a lipidomics approach. PLoS One, 4, e5258.
20. Graessler, J., Schwudke, D., Schwarz, P.E., Herzog, R., Shevchenko, A., and Bornstein, S.R. (2009) Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One, 4, e6261.
21. Guerrera, I.C., Astarita, G., Jais, J.P., Sands, D., Nowakowska, A., Colas, J., Sermet-Gaudelus, I., Schuerenberg, M., Piomelli, D., Edelman, A., and Ollero, M. (2009) A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. PLoS One, 4, e7735.
22. Ikonen, E. (2008) Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell Biol., 9, 125-138.
23. Olson, R.E. (1998) Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J. Nutr., 128, 439S-443S.
24. Mansbach, C.M. and Siddiqi, S.A. (2010) The biogenesis of chylomicrons. Annu. Rev. Physiol., 72, 315-333.
25. Gibbons, G.F., Wiggins, D., Brown, A.M., and Hebbachi, A.M. (2004) Synthesis and function of hepatic very-low-density lipoprotein. Biochem. Soc. Trans., 32, 59-64.
26. Berneis, K.K. and Krauss, R.M. (2002) Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid Res., 43, 1363-1379.
27. Esterbauer, H., Gebicki, J., Puhl, H., and Jurgens, G. (1992) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Biol. Med., 13, 341-390.
28. Itabe, H. (2003) Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol. Pharm. Bull., 26, 1-9.
29. Rosenson, R.S., Brewer, H.B., Jr., Chapman, M.J., Fazio, S., Hussain, M.M., Kontush, A., Krauss, R.M., Otvos, J.D., Remaley, A.T., and Schaefer, E.J. (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem., 57, 392-410.
30. Camont, L., Chapman, M.J., and Kontush, A. (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med., 17 (10), 594-603.
31. Huang, R., Silva, R.A., Jerome,W.G., Kontush, A., Chapman, M.J., Curtiss, L.K., Hodges, T.J., and Davidson, W.S. (2011) Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat. Struct. Mol. Biol., 18, 416-422.
32. Rye, K.A. and Barter, P.J. (2004) Formation and metabolism of prebetamigrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol., 24, 421-428.
33. Rothblat, G.H. and Phillips, M.C. (2010) High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol., 21, 229-238.
34. von Eckardstein, A., Nofer, J.R., and Assmann, G. (2001) High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol., 21, 13-27.
35. Chapman, M.J., Le Goff, W., Guerin, M., and Kontush, A. (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J., 31, 149-164.
36. Santamarina-Fojo, S., Gonzalez-Navarro, H., Freeman, L.,Wagner, E., and Nong, R. (2004) Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol, 24, 1750-1754.
37. Curtiss, L.K., Valenta, D.T., Hime, N.J., and Rye, K.A. (2006) What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler. Thromb. Vasc. Biol., 26, 12-19.
38. Pruzanski, W., Stefanski, E., de Beer, F.C., de Beer, M.C., Ravandi, A., and Kuksis, A. (2000) Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J. Lipid Res., 41, 1035-1047.
39. Ojala, P.J., Hermansson, M., Tolvanen, M., Polvinen, K., Hirvonen, T., Impola, U., Jauhiainen, M., Somerharju, P., and Parkkinen, J. (2006) Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry, 45, 14021-14031.
40. Scherer, M., Bottcher, A., Schmitz, G., and Liebisch, G. (2011) Sphingolipid profiling of human plasma and FPLC-separated lipoprotein fractions by hydrophilic interaction chromatography tandem mass spectrometry. Biochim. Biophys. Acta, 1811, 68-75.
41. Lee, J.Y., Min, H.K., Choi, D., and Moon, M.H. (2010) Profiling of phospholipids in lipoproteins by multiplexed hollow fiber flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry. J. Chromatogr. A, 1217, 1660-1666.
42. Hidaka, H., Hanyu, N., Sugano, M., Kawasaki, K., Yamauchi, K., and Katsuyama, T. (2007) Analysis of human serum lipoprotein lipid composition using MALDI-TOF mass spectrometry. Ann. Clin. Lab Sci., 37, 213-221.
43. Subbaiah, P.V. and Liu, M. (1996) Comparative studies on the substrate specificity of lecithin:cholesterol acyltransferase towards the molecular species of phosphatidylcholine in the plasma of 14 vertebrates. J. Lipid Res., 37, 113-122.
44. Maeba, R. and Ueta, N. (2003) Ethanolamine plasmalogen and cholesterol reduce the total membrane oxidizability measured by the oxygen uptake method. Biochem. Biophys. Res. Commun., 302, 265-270.
45. Maeba, R. and Ueta, N. (2003) Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J. Lipid Res., 44, 164-171.
46. Davidson, W.S., Sparks, D.L., Lund-Katz, S., and Phillips, M.C. (1994) The molecular basis for the difference in charge between pre-beta- and alphamigrating high density lipoproteins. J. Biol. Chem., 269, 8959-8965.
47. Boucher, J.G., Nguyen, T., and Sparks, D. L. (2007) Lipoprotein electrostatic properties regulate hepatic lipase association and activity. Biochem. Cell Biol., 85, 696-708.
48. Deguchi, H., Fernandez, J.A., Hackeng, T. M., Banka, C.L., and Griffin, J.H. (2000) Cardiolipin is a normal component of human plasma lipoproteins. Proc. Natl. Acad. Sci. USA, 97, 1743-1748.
49. Morrow, J.D. (2005) Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol., 25, 279-286.
50. Proudfoot, J.M., Barden, A.E., Loke, W.M., Croft, K.D., Puddey, I.B., and Mori, T.A. (2009) HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J. Lipid Res., 50, 716-722.
51. Nilsson, A. and Duan, R.D. (2006) Absorption and lipoprotein transport of sphingomyelin. J. Lipid Res., 47, 154-171.
52. Rye, K.A., Hime, N.J., and Barter, P.J. (1996) The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J. Biol. Chem., 271, 4243-4250.
53. Saito, H., Arimoto, I., Tanaka, M., Sasaki, T., Tanimoto, T., Okada, S., and Handa, T. (2000) Inhibition of lipoprotein lipase activity by sphingomyelin: role of membrane surface structure. Biochim. Biophys. Acta, 1486, 312-320.
54. Lucke, S. and Levkau, B. (2010) Endothelial functions of sphingosine-1-phosphate. Cell Physiol. Biochem., 26, 87-96.
55. Scherer, M., Bottcher, A., Schmitz, G., and Liebisch, G. (2010) Sphingolipid profiling of human plasma and FPLC-separated lipoprotein fractions by hydrophilic interaction chromatography tandem mass spectrometry. Biochim. Biophys. Acta, 1181 (2): 68-75.
56. Pappu, R., Schwab, S.R., Cornelissen, I., Pereira, J.P., Regard, J.B., Xu, Y., Camerer, E., Zheng, Y.W., Huang, Y., Cyster, J.G., and Coughlin, S.R. (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1- phosphate. Science, 316, 295-298.
57. Yatomi, Y., Ruan, F., Hakomori, S., and Igarashi, Y. (1995) Sphingosine-1- phosphate: a platelet-activating sphingolipid released from agoniststimulated human platelets. Blood, 86, 193-202.
58. Bode, C., Sensken, S.C., Peest, U., Beutel, G., Thol, F., Levkau, B., Li, Z., Bittman, R., Huang, T., Tolle, M., van der Giet, M., and Graler, M.H. (2010) Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J. Cell Biochem., 109, 1232-1243.
59. Nofer, J.-R. and Assmann, G. (2005) Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med., 15, 265-271.
60. Dawson, G., Kruski, A.W., and Scanu, A.M. (1976) Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypoand hyperlipidemias. J. Lipid Res., 17, 125-131.
61. Senn, H.J., Orth, M., Fitzke, E., Wieland, H., and Gerok,W. (1989) Gangliosides in normal human serum: concentration, pattern and transport by lipoproteins. Eur. J. Biochem., 181, 657-662.
62. Burkard, I., von Eckardstein, A., Waeber, G., Vollenweider, P., and Rentsch, K.M. (2007) Lipoprotein distribution and biological variation of 24S- and 27- hydroxycholesterol in healthy volunteers. Atherosclerosis, 194, 71-78.
63. Tikkanen, M.J., Vihma, V., Jauhiainen, M., Hockerstedt, A., Helisten, H., and Kaamanen, M. (2002) Lipoproteinassociated estrogens. Cardiovasc Res., 56, 184-188.
64. Lalanne, F., Pruneta, V., Bernard, S., and Ponsin, G. (1999) Distribution of diacylglycerols among plasma lipoproteins in control subjects and in patients with non-insulin-dependent diabetes. Eur. J. Clin. Invest., 29, 139-144.
65. Havel, R.J., Eder, H.A., and Bragdon, J.H. (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest., 34, 1345-1353.
66. Chapman, M.J., Goldstein, S., Lagrange, D., and Laplaud, P.M. (1981) A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res., 22, 339-358.
67. Guerin, M., Lassel, T.S., Le Goff, W., Farnier, M., and Chapman, M.J. (2000) Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol., 20, 189-197.
68. Kontush, A. and Chapman, M.J. (2006) Antiatherogenic small, dense HDL: guardian angel of the arterial wall? Nat. Clin. Pract. Cardiovasc. Med., 3, 144-153.
69. Lee, C.Y., Lesimple, A., Larsen, A.,Mamer, O., and Genest, J. (2005) ESI-MS quantitation of increased sphingomyelin in Niemann-Pick disease type B HDL. J. Lipid Res., 46, 1213-1228.
70. Glass, C.K. and Witztum, J.L. (2001) Atherosclerosis. the road ahead. Cell, 104, 503-516.
71. Iwase, M., Sonoki, K., Sasaki, N., Ohdo, S., Higuchi, S., Hattori, H., and Iida, M. (2008) Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis, 196, 931-936.
72. Yetukuri, L., Soderlund, S., Koivuniemi, A., Seppanen-Laakso, T., Niemela, P.S., Hyvonen, M., Taskinen, M.-R., Vattulainen, I., Jauhiainen, M., and Oresic, M. (2010) Composition and lipid spatial distribution of HDL particles in subjects with low and high HDLcholesterol. J. Lipid Res., 51, 2341-2351.
73. Yetukuri, L., Huopaniemi, I., Koivuniemi, A., Maranghi, M., Hiukka, A., Nygren, H., Kaski, S., Taskinen, M.R., Vattulainen, I., Jauhiainen, M., and Oresic, M. (2011) High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS One, 6, e23589.
74. Hiukka, A., Stahlman, M., Pettersson, C., Levin, M., Adiels, M., Teneberg, S., Leinonen, E.S., Hulten, L.M., Wiklund, O., Oresic, M., Olofsson, S.O., Taskinen, M.R., Ekroos, K., and Boren, J. (2009) ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes, 58, 2018-2026.
75. Forte, T.M., Bielicki, J.K., Goth-Goldstein, R., Selmek, J., and McCall, M.R. (1995) Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoproteinspecific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J. Lipid Res., 36, 148-157.
76. Argraves, K.M., Sethi, A.A., Gazzolo, P.J., Wilkerson, B.A., Remaley, A.T., Tybjaerg- Hansen, A., Nordestgaard, B.G., Yeatts, S.D., Nicholas, K.S., Barth, J.L., and Argraves,W.S. (2011) S1P, dihydro-S1P and C24:1-ceramide levels in the HDLcontaining fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis., 10, 70.
77. Schissel, S.L., Tweedie-Hardman, J., Rapp, J.H., Graham, G., Williams, K.J., and Tabas, I. (1996) Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein: proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest., 98, 1455-1464.
78. Flood, C., Gustafsson, M., Pitas, R.E., Arnaboldi, L., Walzem, R.L., and Boren, J. (2004) Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of lowdensity lipoprotein-containing human apolipoprotein B100. Arterioscler. Thromb. Vasc. Biol., 24, 564-570.
79. Fanani, M.L. and Maggio, B. (1997) Mutual modulation of sphingomyelinase and phospholipase A2 activities against mixed lipid monolayers by their lipid intermediates and glycosphingolipids. Mol. Membr. Biol., 14, 25-29.
80. Morgantini, C., Natali, A., Boldrini, B., Imaizumi, S., Navab, M., Fogelman, A.M., Ferrannini, E., and Reddy, S.T. (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes, 60, 2617-2623.
81. Oresic, M. (2011) Informatics and computational strategies for the study of lipids. Biochim. Biophys. Acta, 4 (2), 121-127.